Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

被引：23

作者：

Moskowitz, Alison J. ^{[1
]}

Advani, Ranjana H. ^{[2
]}

Bartlett, Nancy L. ^{[3
]}

Vose, Julie M. ^{[4
]}

Ramchandren, Radhakrishnan ^{[5
]}

Feldman, Tatyana A. ^{[6
]}

LaCasce, Ann S. ^{[7
]}

Christian, Beth A. ^{[8
]}

Ansell, Stephen M. ^{[9
]}

Moskowitz, Craig H. ^{[10
]}

Brown, Lisa ^{[11
]}

Taft, David ^{[11
]}

Ansari, Sahar ^{[11
]}

Zak, Daniel E. ^{[11
]}

Sacchi, Mariana ^{[12
]}

Manley, Thomas ^{[11
]}

Herrera, Alex F. ^{[13
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[2] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA

[3] Washington Univ, Sch Med, St Louis, MO USA

[4] Univ Nebraska Med Ctr, Div Hematol Oncol, Omaha, NE USA

[5] Karmanos Canc Inst, Detroit, MI USA

[6] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] James Canc Hosp, Columbus, OH USA

[9] Mayo Clin, Rochester, MN USA

[10] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[11] Seattle Genet Inc, Bothell, WA USA

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122576

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

238

引用

页数：8

共 50 条

[31] Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study
Armand, Philippe
Engert, Andreas
Younes, Anas
Lee, Hun Ju
Santoro, Armando
Zinzani, Pier Luigi
Timmerman, John M.
Collins, Graham P.
Ramchandren, Radhakrishnan
Cohen, Jonathon B.
De Boer, Jan Paul
Savage, Kerry J.
Kuruvilla, John
Trneny, Marek
Shipp, Margaret A.
Sacchi, Mariana
Ansell, Anne Sumbuland Stephen M.
Ansell, Stephen M.
BLOOD, 2018, 132
[32] Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN plus AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)
Lee, Hun
Flinn, Ian W.
Melear, Jason
Ramchandren, Rod
Friedman, Judah
Burke, John M.
Linhares, Yuliya
Gonzales, Paul Alan
Raval, Mihir
Chintapatla, Rangaswamy
Feldman, Tatyana
Yimer, Habte
Islas-Ohlmayer, Miguel
Dean, Asad
Rana, Vishal
Gandhi, Mitul
Renshaw, John
Ho, Linda
Fanale, Michelle A.
Guo, Wenchuan
Yasenchak, Christopher A.
BLOOD, 2022, 140
[33] Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN plus AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)
Lee, Hun Ju
Abramson, Jeremy S.
Bartlett, Nancy L.
Burke, John M.
Lynch, Ryan C.
Eva, Domingo Domenech
Hess, Brian T.
Schuster, Steven R.
Linhares, Yuliya
Ramchandren, Rod
Gandhi, Mitul
Mowat, Rex
Shah, Harsh
Rossi, Giuseppe
Hahn, Uwe H.
Prince, Henry Miles
Ho, Linda
Guo, Wenchuan
Yasenchak, Christopher A.
Straus, David J.
BLOOD, 2022, 140 : 9399 - 9401
[34] Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial (vol 19, pg 257, 2018)
O'Connor, O. A.
Lue, J. K.
Sawas, A.
LANCET ONCOLOGY, 2018, 19 (03): : E137 - E137
[35] Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)
Advani, Ranjana H.
Moskowitz, Alison J.
Bartlett, Nancy L.
Vose, Julie M.
Ramchandren, Radhakrishnan
Feldman, Tatyana A.
LaCasce, Ann S.
Christian, Beth A.
Ansell, Stephen M.
Moskowitz, Craig H.
Fenton, Keenan
Ogden, Carol Anne
Taft, David
Zak, Daniel E.
Sacchi, Mariana
Galderisi, Faith
Herrera, Alex F.
BLOOD, 2018, 132
[36] Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
Moskowitz, Alison J.
Schoder, Heiko
Lee, Jisun
Davey, Theresa
Hancock, Helen
Hamlin, Paul A.
Horwitz, Steven M.
Kumar, Anita
Matasar, Matthew J.
Noy, Ariela
Palomba, M. Lia
Shah, Gunjan L.
Perales, Miguel-Angel
Sauter, Craig S.
Straus, David J.
Younes, Anas
Zelenetz, Andrew D.
Yahalom, Joachim
Moskowitz, Craig H.
BLOOD, 2019, 134
[37] Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients
Gandolfi, Letizia
Pellegrini, Cinzia
Casadei, Beatrice
Stefoni, Vittorio
Broccoli, Alessandro
Tonialini, Lorenzo
Morigi, Alice
Argnani, Lisa
Zinzani, Pier Luigi
ONCOLOGIST, 2016, 21 (12): : 1436 - 1441
[38] Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results
Cao, Xinxin
Jin, Jie
Cheng, Fu Cheng
Yi, Shuhua
Zhao, Weili
Sun, Zimin
Yang, Wei
Li, Dengju
Cui, Guohui
Hu, Jianda
Liu, Ting
Song, Yongping
Xu, Bing
Zhu, Zunmin
Xu, Wei
Zhang, Mingzhi
Li, Sichen
Wang, Weige
Zhao, Renbin
Zhou, Daobin
BLOOD, 2023, 142
[39] Immune Landscape Associated with Response to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Relapsed/Refractory Hodgkin Lymphoma (E4412 Phase 1)
Diefenbach, Catherine S.
Gonzalez-Kozlova, Edgar
Del Valle, Diane Marie
Huang, Hsin-Hui
Jegede, Opeyemi
Barcessat, Vanessa
Tuballes, Kevin
Kelly, Geoffrey
Patel, Manishkumar
Xie, Hui
Harris, Jocelyn
Argueta, Kimberly
Nie, Kai
Moravec, Radim
Altreuter, Jennifer
Duose, Dzifa Yawa
Kahl, Brad S.
Ansell, Stephen M.
Yu, Joyce
Cerami, Ethan
Lindsay, James
Wistuba, Ignacio
Kim-Schulze, Seunghee
Gnjatic, Sacha
BLOOD, 2023, 142
[40] A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Song, Yuqin
Wu, Jianqiu
Chen, Xinchuan
Lin, Tongyu
Cao, Junning
Liu, Yanyan
Zhao, Yaozhong
Jin, Jie
Huang, Haiwen
Hu, Jianda
Luo, Jun
Zhang, Liling
Xue, Hongwei
Zhang, Qingyuan
Wang, Weiwei
Chen, Chunxia
Feng, Jifeng
Zhu, Jun
CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7363 - 7369

← 1 2 3 4 5 →